Want to see KVUE full AI Analyst Report?
KVUE Stock Chart & Stats
$17.61
-$0.04(-0.19%)
At close: 4:00 PM EST
$17.61
-$0.04(-0.19%)
Day’s Range― - ―
52-Week Range$14.02 - $22.87
Previous CloseN/A
Volume2.33M
Average Volume (3M)21.08M
Market Cap
$38.07B
Enterprise Value$42.17B
Total Cash (Recent Filing)$1.07B
Total Debt (Recent Filing)$8.66B
Price to Earnings (P/E)23.3
Beta<0.01
Next Earnings
Aug 12, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend Yield4.85%
Share Statistics
EPS (TTM)0.85
Shares Outstanding1,920,008,700
10 Day Avg. Volume17,782,433
30 Day Avg. Volume21,079,545
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)3.06
Price to Sales (P/S)2.18
P/FCF Ratio19.14
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit4.72
Enterprise Value/Ebitda13.30
Forecast
1Y Price Target
$18.80Price Target Upside6.76% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)1.19
Revenue Forecast (FY)$15.64B
Bulls Say, Bears Say
Bulls Say
Brand Portfolio StrengthKenvue’s diversified portfolio of household consumer-health brands across multiple staple categories supports resilient, repeat purchase demand and broad retail distribution. This brand equity reduces revenue volatility, sustains shelf placement and promotional leverage, and underpins durable cash flows and margins over time.
Strong Cash Generation & FCF ConversionConsistent, sizable free cash flow and high conversion of earnings into cash provide financing flexibility for dividends, reinvestment, and debt servicing. Over a multi-month horizon this cash generation enhances balance sheet resilience and the company’s ability to fund brand investment or strategic moves without relying on external capital.
Healthy Gross Margins & ProfitabilityMargins near 58% are strong for consumer health, signaling product mix and pricing power. Sustained gross and net margins support free cash flow, dividend capacity, and reinvestment in marketing/innovation, making profitability a durable structural advantage versus lower-margin peers in adjacent segments.
Bears Say
Low Organic Revenue GrowthA largely flat top line and only modest recent growth constrain long-term earnings upside. With limited organic expansion, the company must rely on pricing, mix shifts, or M&A to materially increase sales, which can be slower and more uncertain than faster-growing consumer or health niches.
Elevated LeverageHigher leverage reduces financial flexibility for M&A, large-scale brand investment, or aggressive buybacks. It raises interest-cost sensitivity to rate moves and can constrain capital allocation choices across a 2–6 month horizon, particularly if cash flow softens or refinancing windows tighten.
Earnings And Cash-flow VolatilityHistoric swings in margins and cash flow reduce predictability of payouts and investment plans. This volatility can complicate multi-quarter planning, increase perceived execution risk, and necessitate larger liquidity buffers, which may temper shareholder returns or constrain strategic initiatives.
Kenvue, Inc. News
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
Kenvue, Inc. lowest stock price was $14.02 and its highest was $22.87 in the past 12 months.
What is Kenvue, Inc.’s market cap?
Kenvue, Inc.’s market cap is $38.07B.
When is Kenvue, Inc.’s upcoming earnings report date?
Kenvue, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 38 days.
How were Kenvue, Inc.’s earnings last quarter?
Kenvue, Inc. released its earnings results on May 07, 2026. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.262 by $0.058.
Is Kenvue, Inc. overvalued?
According to Wall Street analysts Kenvue, Inc.’s price is currently Undervalued.
Does Kenvue, Inc. pay dividends?
Kenvue, Inc. pays a Quarterly dividend of $0.207 which represents an annual dividend yield of 4.85%. See more information on Kenvue, Inc. dividends here
What is Kenvue, Inc.’s EPS estimate?
Kenvue, Inc.’s EPS estimate is 0.32.
How many shares outstanding does Kenvue, Inc. have?
Kenvue, Inc. has 1,920,008,700 shares outstanding.
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Kenvue, Inc. reported an EPS of $0.32 in its last earnings report, beating expectations of $0.262. Following the earnings report the stock price went up 0.223%.
Which hedge fund is a major shareholder of Kenvue, Inc.?
Currently, no hedge funds are holding shares in KVUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kenvue, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$18.80 (6.76% Upside)
$18.80 (6.76% Upside)
Blogger Sentiment
Bullish
KVUE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 19.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $746.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.3%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.71%
12-Months-Change
Fundamentals
Return on Equity
15.18%
Trailing 12-Months
Asset Growth
2.27%
Trailing 12-Months
Company Description
Kenvue, Inc.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
KVUE Revenue Breakdown
42.17% Self Care
27.20% Skin Health and Beauty
30.63% Essential Health
KVUE Stock 12 Month Forecast
Average Price Target
$18.80
▲(6.76% Upside)
Technical Analysis
Ownership Overview
1.45% Insiders
24.24% Mutual Funds
0.02% Other Institutional Investors
44.77% Public Companies and Individual Investors